Study results for cancer treatment boost OSE Immunotherapeutics shares

Ose Immunotherapeutics SA

15/11/2021 09:23

** Shares in OSE Immunotherapeutics  OSE.PA  jump around
8%after the biotechnology company announced pre-clinical data on
its myeloid cell immune checkpoint target CLEC-1 for cancer
immunotherapy
    ** For the first time, CLEC-1 displayed "significant
preclinical efficacy," the company said  urn:newsml:reuters.com:*:nBw2Tnr4ya
    ** The stock is on track for its best day since Sept. 20
    ** All eight analysts who cover OSE Immunotherapeutics rate
the stock "strong buy/buy"​ 

 (Reporting by Olivier Sorgho)
 ((olivier.sorgho@tr.com))